Hip dysplasia is one of the most common orthopedic diagnoses in herding breeds, and for an MDR1-affected dog it creates a doubled worry: the joint disease needs pain control for years, and a few of the drugs veterinarians reach for out of habit are exactly the ones the mutation makes risky. The reassuring part is that the foundation of dysplasia pain control, the NSAID class, sits outside the problem list entirely. The care is needed in the add-on drugs.
This article covers the medication side only. For the orthopedic picture itself, including radiograph scores, surgical options, and week-by-week recovery, a shepherd hip dysplasia resource written from twenty-five years of operating on German Shepherds and other herding breeds covers that ground in detail.
Which pain drugs can an MDR1 dog with dysplasia take?
The everyday answer is: nearly all of the routine ones. The standard anti-inflammatories used for canine arthritis and post-surgical pain are not meaningful P-glycoprotein substrates, so the mutation does not change how they are dosed.
- Carprofen, meloxicam, firocoxib, robenacoxib and the other veterinary NSAIDs are the backbone of dysplasia management and are used at normal doses in MDR1 dogs.
- Grapiprant (Galliprant), the targeted osteoarthritis drug, is also outside the P-gp system.
- Gabapentin and amantadine, the common nerve-pain add-ons, are not P-glycoprotein substrates either.
- Bedinvetmab (Librela), the monthly osteoarthritis injection, is a monoclonal antibody and not an MDR1 concern.
Our broader pain management guide for MDR1 dogs goes drug by drug through this list, including the normal kidney and liver monitoring that applies to every dog on long-term NSAIDs.
Where does the real caution sit?
The drugs that deserve a second question are the opioids sometimes added for breakthrough pain. Butorphanol is the classic trap: it is a P-glycoprotein substrate, it produces deeper and longer sedation in affected dogs, and it is a weak analgesic to begin with. If a discharge plan leans on butorphanol for a painful hip, it is reasonable to ask whether a stronger and safer option fits better.
The stronger opioids such as morphine, fentanyl, and buprenorphine sit in a “less defined” zone rather than on the banned list. When a dysplastic MDR1 dog needs surgery or has a genuinely painful flare, the accepted approach is to use them at the low end of the dose range with closer monitoring, not to leave the dog in pain. Untreated pain slows recovery and is a welfare problem of its own.
What does day-to-day management look like beyond medication?
Medication is only one leg of dysplasia care, and for an MDR1 dog it is the leg where the fewest changes are needed. The rest of the plan is the same as for any herding breed:
- Weight control, because every extra kilogram multiplies the load on a malformed hip.
- Adjusted exercise, favoring regular moderate activity and swimming over weekend sprints.
- Physical rehabilitation, which preserves muscle that stabilizes the joint.
- Environmental changes like ramps and non-slip flooring that prevent the slips that turn a manageable joint into an acute injury.
For families weighing screening and grading, the Orthopedic Foundation for Animals hip dysplasia overview explains how the radiograph evaluation and the OFA grading system work, which is useful context before any surgical discussion.
What if surgery is recommended for an MDR1 dog?
Severe dysplasia sometimes ends up at a total hip replacement or a femoral head ostectomy, and MDR1 does not rule either out. It does change the anesthesia conversation: sedatives like acepromazine need review, pre-medication doses may be lowered, and recovery monitoring should assume that any P-gp drug given will clear more slowly. The full checklist for that conversation is in our sedation and anesthesia guide, which pairs naturally with the surgical recovery timelines on the orthopedic side.
The short version
A dysplastic MDR1 dog is not a dog who cannot have pain relief. NSAIDs, grapiprant, gabapentin, amantadine, and the newer injectable options are all used normally. The adjustments happen around opioids, especially butorphanol, and around anesthesia if surgery is chosen. Bring the genotype into every prescription conversation, question the habitual weak opioids, and the joint disease can be managed on essentially the same plan any other shepherd would get.